Journal
NATURE MEDICINE
Volume 26, Issue 5, Pages 688-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-020-0856-x
Keywords
-
Funding
- Bristol-Myers Squibb
- Yale SPORE in Lung Cancer [P50CA196530]
- Department of Defense-Lung Cancer Research Program [W81XWH-16-1-0160]
- Yale Cancer Center Support Grant [P30CA016359]
- Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team Translational Research Grant [SU2C-AACR-DT1715, SU2C-AACR-DT22-17]
- Mark Foundation [19-029-MIA]
- MINECO [SAF2017-83267-C2-1-R]
- European Union's Horizon 2020 research and innovation program [635122]
- Fundacion de la Asociacion Espanola Contra el Cancer (AECC)
- Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (Spain)
Ask authors/readers for more resources
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available